Raymond James lowers Intuitive Surgical stock price target on valuation
Raymond James reduced its price target for Intuitive Surgical (ISRG) to $480 from $483, keeping an Outperform rating. The firm raised estimates after ISRG's Q3 results showed 22% revenue growth and 25% EPS growth, beating expectations. ISRG reported Q3 2026 adjusted earnings of $3.00 per share (vs. $2.65 expected) and revenue of $3.05B (vs. $2.91B expected), with shares declining in after-hours trading.
How this was made
The 30-second read
Why it matters
The analyst downgrade provides a new data point for traders; the modest target reduction may prompt short‑term selling but the underlying growth remains robust.
Market read
A fresh analyst price‑target cut on a high‑growth medical‑technology leader offers a short‑term trading signal while the longer‑term growth narrative stays intact.
What to watch
International market expansion and rising procedure volumes could sustain upside despite the modest target reduction.
Background
Raymond James adjusted its valuation model for Intuitive Surgical after the company's Q3 earnings beat expectations on revenue and EPS.
Ticker impact
Raymond James lowered its price target on Intuitive Surgical to $480 from $483 after the company's Q3 results.
likely slight downward pressure as investors price in the lower target
The target reduction is a fresh analyst action; the cut is small but signals concerns about valuation despite strong earnings.
Market effects
Medical‑robotics sector may see modest re‑rating as peers follow the target cut.
U.S. equities, particularly healthcare stocks, could feel slight pressure.
Limited to investors tracking Intuitive Surgical and related robotics firms.
Counterpoint
The target cut may be overly cautious given the company's strong growth and margin expansion.
Key entities
- companyIntuitive Surgical
Manufacturer of da Vinci surgical robots.
- analyst_firmRaymond James
Equity research firm that issued the price‑target change.
